EBI-1051

an orally efficacious MEK inhibitor; structure in first source

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 01/01/2018 - "Compared to AZD6244, EBI-1051 showed superior potency in some cancer cell lines such as colon-205, A549 and MDA-MB-231." 01/01/2018 - "One of the compounds EBI-1051 (28d) demonstrated excellent in vivo efficacy in colo-205 tumor xenograft models in mouse and is suitable for pre-clinical development studies for the treatment of melanoma and MEK associated cancers. "
2.	Melanoma (Melanoma, Malignant) 01/01/2018 - "One of the compounds EBI-1051 (28d) demonstrated excellent in vivo efficacy in colo-205 tumor xenograft models in mouse and is suitable for pre-clinical development studies for the treatment of melanoma and MEK associated cancers. "

1.	Mitogen-Activated Protein Kinase Kinases (MEKs)
2.	AZD 6244